CCDC134

Across TCGA pan-cancer cohorts, CCDC134 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of CCDC134’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CCDC134 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CCDC134 is over-expressed in tumor, although a few such as THCA and KIRP show the opposite, repressed pattern.

BLCA, HNSC, and LIHC are the cancer types where CCDC134 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCDC134 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	III,IV	+1.141	<.001	11	view →
HNSC	Male	All	+0.823	<.001	11	view →
LIHC	Female	II,III,IV	+1.420	<.001	9	view →
LUAD	Female	All	+0.649	<.001	9	view →
STAD	Male	II,III,IV	+1.106	<.001	8	view →
LUSC	All	II,III,IV	+1.075	<.001	7	view →
KICH	All	II,III,IV	+0.828	<.001	7	view →
THCA	All	All	−0.303	<.001	7	view →
UCEC	All	All	+0.821	<.001	6	view →
COAD	Female	II,III,IV	+0.596	<.001	6	view →
CHOL	Male	All	+1.756	<.001	5	view →
BRCA	All	II,III,IV	+0.334	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

CCDC134–BLCA

Open the BLCA breakdown →